Clovis receives NICE recommendation for rucaparib access through CDF
Clovis announced that the National Institute for Health and Care Excellence, or NICE, has recommended that women with relapsed ovarian cancer in England have access to rucaparib through the Cancer Drugs Fund, or CDF. Rucaparib is available for use within the CDF as an option for the maintenance treatment of relapsed, platinum-sensitive high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer that has responded to platinum-based chemotherapy in adults, based on the conditions outlined in the managed access agreement. The European Union conditional marketing authorization is based on data from the pivotal Phase 3 ARIEL3 clinical trial. ARIEL3 successfully achieved its primary endpoint of extending investigator-assessed PFS versus placebo in all patients treated, population, regardless of BRCA status.